Respiratory Drug Discovery

Charles River has a long history of experience with all aspects of respiratory therapy research – from discovery of novel compounds and efficacy evaluation to safety evaluation by all clinical routes, including inhalation. Since 2005, our scientists have been named as co-inventors on nearly 70 patents for novel compounds for respiratory indications and have delivered 25 preclinical development candidates in this area.

Our scientists can help you manage the unique challenges associated with your respiratory discovery program.

Ask a respiratory expert »

Webinars

Posters

2016

2015

  • Tetrahydrotriazolopyrimidine Derivatives, Pharmaceutical Compositions Containing the Same and Uses (WO/2015/189362)
  • Novel Compounds (WO/2015/188866)
  • Carbamate Derivatives Which Are Both Phosphodiesterase 4 (PDE4) Enzyme Inhibitors and Muscarinic M3 Receptor Antagonists (WO/2015/185650)
  • Aminoester Derivatives (WO/2015/185649)
  • 3,5-Dichloro,4-(3,4-(Cyclo-)Alkoxyphenyl)-2-Arbonyloxy)Ethyl)Pyridine Derivatives as PDE -4 Inhibitors (WO/2015/185130)
  • 3,5-Dichloro,4-(3,4-(Cyclo-)Alkoxyphenyl)-2-Carbonyloxy)Ethyl)Pyridine Derivatives as PDE-4 Inhibitors (WO/2015/185128)
  • 5-Chloro-2-Difluoromethoxyphenyl Pyrazolopyrimidine Compounds Which Are Jak Inhibitors (WO/2015/177326)
  • Tetrahydrotriazolopyrimidine Derivatives as Human Neutrophil Elastase Inhibitors (WO/2015/091281)
  • Benzhydryl Derivatives for the Treatment of Respiratory Diseases (WO/2015/082619)
  • Heteroaryl Derivatives for the Treatment of Respiratory Diseases (WO/2015/082616)
  • Triazolopyridine Compounds, Compositions and Methods of Use Thereof (WO/2015/032286)

2014

2013

  • Kinase Inhibitors (WO/2013/083606)
  • Kinase Inhibitors (WO/2013/083604)
  • Derivatives of 4-Hydroxy-1,2,3,4-Tetrahydronaphtalen-1-yl Urea and Their Use in the Treatment of, Inter Alia, Diseases of the Respiratory Tract (WO/2013/083206)
  • Tetrahydrotriazolopyrimidine Derivatives as Human Neutrophil Elastase Inhibitors (WO/2013/037809)

2012

  • Compounds Having Muscarinic Recelptor Antagonist and Beta-2 Andrenergic Receptor Agonist Activity (WO/2012/168359)
  • Compounds Having Muscarinic Recelptor Antagonist and Beta-2 Andrenergic Receptor Agonist Activity (WO/2012/168349)

2011

  • Urea Derivatives and Their Therapeutic Use in the Treatment of, Inter Alia, Diseases of the Respiratory Tract (WO/2011/154738)
  • Compounds (WO/2011/154678)
  • Pyrimidine Derivatives and Their Use in the Treatment of Respiratory Diseases Such as COPD (WO/2011/110859)
  • Pyrimidine Derivatives and Their Use in the Treatment of Respiratory Diseases Such as COPD (WO/2011/110858)
  • Crystalline Acid Addition Salts of (5R)-Enantiomer of Pioglitazone (WO/2011/098746)
  • Enantiomeric Resolution Method (WO/2011/015868)

2010

  • 5R-5-Deuterated Glitazones for Respiratory Disease Treatment (WO/2010/150014)
  • Indole Derivatives as Ligands of Crth2 Receptors (WO/2010/142934)
  • Pyridylurea Derivatives and Their Therapeutic Use (WO/2010/131030)
  • Triazolopyridine Derivatives as P38 Map Kinase Inhibitors (WO/2010/094956)
  • Pyrimidopyridazine Derivatives Useful as P38 Inhibitors (WO/2010/094955)
  • Dimeric Pyrrolopyrimidinedione and Its Use in Therapy of Respiratory Diseases (WO/2010/086638)
  • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Second Active Ingredient (WO/2010/071582)
  • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a B2-Adrenoceptor Agonist (WO/2010/071581)
  • Diazaspiro[5.5] Undecane Derivatives and Related Compounds as Muscarinic-Receptor Antagonists and Beta-Adrenoreceptor Agonists for the Treatment of Pulmonary Disorders (WO/2010/067102)
  • 2-Hydroxy-Ethanesulfonate Salt (WO/2010/019099)
  • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Beta-2-Adrenoceptor Agonist (WO/2010/019098)
  • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Second Active Ingredient (WO/2010/019097)
  • Heterocyclic Compounds Used in the Treatment of Diseases Where Enhanced M3 Receptor Activation Is Implicated (WO/2010/018352)
  • Nitrogen Containing Heterocyclic Compounds Useful as Bifunctional Modulators of M3 Receptors and Beta-2 Receptors (WO/2010/015792)

2009

  • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Βeta2-Adrenoceptor Agonist (WO/2009/139708)
  • Pharmaceutical Product Comprising a Muscarinic Receptor Antagonist and a Second Active Ingredient (WO/2009/139707)
  • Quinuclidine Derivatives as Muscarinic M3 Receptor Antagonists (WO/2009/138707)
  • 2- (9H-Xanthen-9-Yl) -Oxazol Derivatives as M3 Muscarinic Receptor Antagonists for the Treatment of Asthma and Chronic Obstructive Lung Disease (WO/2009/098455)
  • Azonia Bicycloalkanes as M3 Muscarinic Acetylcholin Receptor Antagonists (WO/2009/098453)
  • Compounds (WO/2009/098448)

2008

  • Bicyclor [2.2.1] Hept-7-Ylamine Derivatives and Their Use in the Treatment of Diseases and Conditions in Which M3 Muscarinic Receptor Activity and Beta-Adrenergic Activity Are Implicated (WO/2008/149110)
  • Bicyclo [2.2.1] Hept- 2-Ylamine Derivates and Their Use (WO/2008/149053)
  • Napadisylate Salt of a Muscarinic M3 Antagonist (WO/2008/096149)
  • Combinations With a Muscarinic Receptor Antagonist (WO/2008/096136)
  • Nitrogen Containing Hetrocyclic Compounds Useful as Bifunctional Modulators of M3 Receptors and Beta-2 Receptors (WO/2008/096129)
  • Bicyclo [2.2.1] Hept-7-Ylamine Derivatives and Their Use as M3 Muscarinic Receptor Modulators (WO/2008/096127)
  • Combination of a Muscarinic Receptor Antagonist and a Beta-2-Adrenoceptor Agonist (WO/2008/096126)
  • Nitrogen Containing Heterocyclic Compounds Useful as M3-Receptor Modulators (WO/2008/023157)

2005

  • Novel Diazaspiroalkanes and Their Use for Treatment of CCR-8 Mediated Diseases (WO/2005/040167)

You may also be interested in...

confocal image of lung tissue following bacterial infection

The Breath of Life is Complex

Read our Eureka blog to learn how we are choreographing the cellular dance of lung repair and what it might mean for respiratory conditions like ARDS and IPF.

Respiratory In Vivo Pharmacology Models

We provide in vivo pharmacology study models covering respiratory diseases, including asthma, severe asthma, COPD, lung fibrosis, cough and mucociliary clearance.